Nature: Nano-CT technique paves way for better osteoporosis diagnosis

A newly developed nano-CT method visualizes minute, fragile bone structure and density changes at high resolutions and in 3D, according to research published Sept. 23 in Nature.

Osteoporosis is diagnosed almost exclusively by establishing an overall reduction in bone density. This approach, however, gives little information about the associated local structure and bone density changes, offered Franz Pfeiffer, PhD, professor for Biomedical Physics at the Technische Universitaet Muenchen in Germany and his colleagues.

According to the authors, the new technique generates quantitative high-contrast 3D electron density maps from phase contrast information without reverting to assumptions of a weak phase object or negligible absorption and measures overall x-ray beam intensity absorbed by the object under examination at each angle. It also measures the diffracted parts of the beam. The diffraction patterns are then processed using an algorithm that was designed for the study, which takes into account both typical x-ray absorption as well as the more sensitive phase shift of the beam.

The researchers utilized a 25-micrometer, superfine bone specimen of a 12-week old laboratory mouse for their study. The CT images showed cross-sections of cavities where bone cells reside and their roughly 100 nanometer-fine interconnection network, they wrote.

“This [approach] enables us to do research on structural changes related to osteoporosis on a nanoscale and thus develop better therapeutic approaches," said Pfeiffer.


Around the web

CMS finalized a significant policy change when it increased the Medicare payments hospitals receive for performing CCTA exams. What, exactly, does the update mean for cardiologists, billing specialists and other hospital employees?

Stryker, a global medtech company based out of Michigan, has kicked off 2025 with a bit of excitement. The company says Inari’s peripheral vascular portfolio is highly complementary to its own neurovascular portfolio.

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.